When BCAT1 is knocked down with shRNA, glioma cell growth is reduced in vitro and in vivo, and when treated with gabapentin, a pharmacological inhibitor of BCAT1, glutamate release is also attenuated. The gene discussed is BCAT1; the disease is glioma.